RAAS polymorphisms alter the acute blood pressure response to aerobic exercise among men with hypertension.
Limited evidence suggests renin-angiotensin-aldosterone system (RAAS) polymorphisms alter the blood pressure (BP) response to aerobic exercise training. We examined if RAAS polymorphisms influenced postexercise hypotension in men with high normal to Stage 1 hypertension. Forty-seven men (44.2+/-1.4 years, 145.1+/-1.6/85.5+/-1.1 mmHg) randomly completed three experiments: seated rest (control) and two cycle exercise bouts at 40% (LITE) and 60% (MOD) of maximal oxygen consumption. Ambulating BP was measured for 14 h after each experiment. RAAS polymorphisms associated with hypertension (i.e. angiotensin converting I enzyme, ACE I/D; angiotensin II type 1 receptor, AT1R A/C; and intron 2 of aldosterone synthase, Int2 W/C) were analyzed using polymerase chain reaction and restriction enzyme digestion. Repeated measure ANOVA tested if BP differed between experimental conditions by RAAS genotypes. Compared to men with 0-2 variant alleles, men with > or =3 combined RAAS variant alleles had lower average systolic BP (SBP) (P=0.030) and lower average diastolic BP (DBP) (P=0.009) for 14 h only after LITE. In contrast, average BP was not different for MOD and control between RAAS variant allele groups over this time period (P> or =0.05). LITE reduced BP in men with > or =3 variant RAAS alleles for 14 h, whereas MOD had no influence on BP in these men. In order to optimally prescribe exercise for its BP lowering benefits in those with hypertension, additional knowledge of how genetic variation affects the BP response to exercise is needed.
Blanchard
Bruce E
BE
University of CT, Storrs, CT 06102, USA. bblanch@harthosp.org
Tsongalis
Gregory J
GJ
Guidry
Margaux A
MA
LaBelle
Lisa A
LA
Poulin
Michelle
M
Taylor
Amy L
AL
Maresh
Carl M
CM
Devaney
Joseph
J
Thompson
Paul D
PD
Pescatello
Linda S
LS
D000328:Adult; D000332:Aerobiosis; D001794:Blood Pressure; D019405:Cytochrome P-450 CYP11B2 / Q000235:genetics; D005080:Exercise Test / Q000009:adverse effects*; D020022:Genetic Predisposition to Disease / Q000235:genetics; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000503:physiopathology*; D007022:Hypotension / Q000209:etiology / Q000503:physiopathology*; D008297:Male; D007703:Peptidyl-Dipeptidase A / Q000235:genetics; D011110:Polymorphism, Genetic; D044139:Receptor, Angiotensin, Type 2 / Q000235:genetics; D012084:Renin-Angiotensin System / Q000235:genetics*
D044139:Receptor, Angiotensin, Type 2; D019405:Cytochrome P-450 CYP11B2; D007703:Peptidyl-Dipeptidase A